Topper Copies

(a) Identify the stakeholders in the above case study. (b) Discuss the ethical issues faced by Dr. Mehra. (c) Analyse the options available to Dr. Mehra in the above case. Which of these would you choose and why?

Akansh Dhull, AIR 3, 2025

After the COVID-19 vaccines like Moderna's long term effects controversy - the case highlights the classic issue of capitalism -> beating others and being market leader but at what cost?

b) Ethical Issues involved

1. Limits to capitalism and greed 2. Responsibility of welfare on private sector 3. Expediency to cure life and its impact on long term health 4. Larger welfare and ends through bad means (eg only small percentage of errors are shown) 5. Level of regulations & scrutiny on pharma companies by government 6. Dr's duty as company employee vs professional ethics (Hippocratic oath) 7. Profits vs goodwill of the company 8. Viability of company as 10 years since project launched 9. Financial security of company employees

c) Options available to Dr Mehra

1. Releasing drug without satisfactory results

| Merit | Demerit | |---|---| | Effectiveness and reach to patients | Ire from government | | Cure received and larger welfare | Crisis of conscience of Doctor as might harm | | Satisfaction of board | Against professional ethics |

2. Withholding drug till final research happens

| Merit | Demerit | |---|---| | Compliance to guideline | Board becoming restless | | No harm to goodwill if any failure | Profitability of pharma company |

Option Chosen :- Mix of Both

1. Persuasion of board about risk of failure and government crackdown 2. Keeping record of all data 3. Expediency in conducting trials with due process 4. Extensive study of sample results

Why? 1. Long term interest of company and society converge. Also that of government 2. Doctor's fiduciary duty towards patient 3. Harm of getting too ahead of oneself.

The case should guide drug developer understanding that their work should be in spirit of social entrepreneurship. Further government should provide funds to ensure viability of corporations.